Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Part of paid clinical trials in Glen Oaks, New York.

Sponsor: Northwell Health
Study ID: NCT07483294
Phase: PHASE4
Status: Recruiting

Apply to this trial

Conditions

Psychosis; Acute

Eligibility Criteria

Sex: ALL
Age: 15 Years - 40 Years
Healthy Volunteers: Not accepted

Interventions

risperidone — DRUG
standard treatment, non-randomized
aripiprazole — DRUG
standard treatment, non-randomized

Study Details

This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.

Key Dates

Start date: Nov 1, 2025
Status verified: Mar 2026
Primary completion: Dec 1, 2029
Completion: Jun 1, 2030

Study Design

Enrollment: 120 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Arms

Experimental: Drug
Open label drugs

Primary Outcome Measure

Cerebellar-cortical functional connectivity [ Time Frame: July 2025 - December 2029 ]

Central Contacts

Hengyi Cao
718-470-5913
[email protected]
Juan Gallego
718-470-4588
[email protected]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Zucker Hillside Hospital	Glen Oaks	New York	11004	Taylor Marzouk [email protected] 718-470-8905

Find similar trials in Glen Oaks, NY

By research site

Zucker Hillside Hospital· Glen Oaks, NY